Mechanism and Regulation of Microglia Polarization in Intracerebral Hemorrhage

Yuting Guo 1,†, Weibo Dai 2,†, Yan Zheng 3,†, Weilin Qiao 4, Weixuan Chen 4, Lihua Peng 4, Hua Zhou 5,*, Tingting Zhao 6,*, Huimin Liu 1,*, Feng Zheng 7,* and Peng Sun 8,*

1 School of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
2 Department of Pharmacy, Zhongshan Hospital of traditional Chinese Medicine, Zhongshan 528401, China
3 Research Center of Translational Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China
4 Zhongshan Zhongzhi Pharmaceutical Group Co., Ltd., Zhongshan 528411, China
5 The Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
6 School of Foreign Languages, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
7 Department of Neurosurgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362002, China
8 Innovation Research Institute of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
* Correspondence: ttz1011@126.com (T.Z.); liuhm3009@163.com (H.L.); dr.fengzheng@gmail.com (F.Z.); sunpeng@sdutcm.edu.cn (P.S.)
† These authors contributed equally to this work.

Abstract: Intracerebral hemorrhage (ICH) is the most lethal subtype of stroke, but effective treatments are lacking, and neuroinflammation plays a key role in the pathogenesis. In the innate immune response to cerebral hemorrhage, microglia first appear around the injured tissue and are involved in the inflammatory cascade response. Microglia respond to acute brain injury by being activated and polarized to either a typical M1-like (pro-inflammatory) or an alternative M2-like (anti-inflammatory) phenotype. These two polarization states produce pro-inflammatory or anti-inflammatory. With the discovery of the molecular mechanisms and key signaling molecules related to the polarization of microglia in the brain, some targets that regulate the polarization of microglia to reduce the inflammatory response are considered a treatment for secondary brain tissue after ICH damage effective strategies. Therefore, how to promote the polarization of microglia to the M2 phenotype after ICH has become the focus of attention in recent years. This article reviews the mechanism of action of microglia’s M1 and M2 phenotypes in secondary brain injury after ICH. Moreover, it discusses compounds and natural pharmaceutical ingredients that can polarize the M1 to the M2 phenotype.

Keywords: intracerebral hemorrhage; microglia polarization; inflammatory response; therapeutic target

1. Introduction

Intracerebral hemorrhage (ICH) is a common acute clinical cerebrovascular disease for which no effective treatment exists. ICH includes traumatic brain hemorrhage (TBI) and non-traumatic brain hemorrhage (ICH). Non-traumatic cerebral hemorrhage also includes intracerebral parenchymal hemorrhage, intraventricular hemorrhage, and subarachnoid hemorrhage, possibly due to primary or secondary causes. Among the risk factors for primary causes of ICH are hypertensive microangiopathy, cerebral amyloid angiopathy, coagulation disorders, drug use and other risk factors, while risk factors for secondary ICH include cavernous hemangioma, smoker’s disease, arteriovenous malformations, and aneurysms [1]. Brain injury ICH is mainly the primary injury caused by the expansion of the hematoma and secondary injury caused by the pathological reaction of the blood.
The hematoma increases intracranial pressure causing mechanical compression of the surrounding brain tissue and decreasing blood flow to the brain, which may result in brain herniation in severe cases. In addition, the severity of the primary injury is related to the location and volume of the hematoma and the degree of edema in the brain tissue surrounding the brain injury. In contrast, secondary injury after brain hemorrhage is complex and includes inflammation, oxidative stress, excitotoxicity, and cytotoxicity [2]. Microglia, key innate immune cells within the brain, are thought to be the first cells to respond to various acute brain injuries, including brain hemorrhage. Previous studies have shown that microglia are activated by exudated blood components after ICH, and activated microglia are a major source of cytokines, chemokines, prostaglandins, proteases, and other immunomodulatory molecules in the brain that bind together to initiate the repair process secondary to brain injury [3,4]. Following an inflammatory response in the CNS, activated microglia and recruited macrophages present some common features (e.g., expression of shared phenotypic markers, ability to polarize to the M1/M2 phenotype, phagocytic behavior, and the amoeboid shape that activated microglia may acquire) [5]. Furthermore, it is difficult to distinguish; however, a broad M1 and M2 type classification remains a useful concept for understanding the functional status of microglia during the development of CNS injury and for exploring new therapeutic strategies [6]. Microglia around the lesion in the early stages of brain hemorrhage are activated and polarized into different phenotypes, including a pro-inflammatory phenotype (M1) and an anti-inflammatory phenotype (M2), which may interact with surrounding brain cells (e.g., neurons, astrocytes, oligodendrocytes) or may depend on the microenvironment in which they are located. Furthermore, the classical binary classification of microglia activated as pro-inflammatory and anti-inflammatory phenotypes is considered too simplistic. Microglia have overlapping functional states, which also need to be considered [7]. For example, M2b-like microglia can produce markers of both inflammation and tissue repair. It was found that, in a mouse model of ischemic stroke, both M1 and M2 phenotypes were present at the site of injury, and M1-related genes (inducible nitric oxide synthase (iNOS), CD1b, CD16, CD32, CD86) were upregulated from day 3 to day 14 after stroke; in contrast, mRNA expression of M2 markers (e.g., macrophage mannose receptor 1 (CD206), arginase 1 (Arg-1), IL-10, transforming growth factor-β (TGF-β)) on day one could be observed, peaking at days 3–5 and returning to pre-injury levels at day 11 [8]. However, in the ICH mouse model of bleeding within six hours, M1 microglia increased rapidly and decreased slowly over 14 days, whereas the M2 phenotype was at a low level on day one and increased by day 14 [3,9]. In addition, the M1 to M2 phenotype switch occurred within the first seven days after ICH, but the exact timing and predisposing factors of the phenotype change are unknown [10]. It was found that inhibiting the pro-inflammatory M1 response without completely eliminating it reduces secondary inflammation-related damage to nerve tissue and can accelerate the regression of damage. Because some inflammation is important to resolve nerve injury and promote repair, a completely dysregulated and persistent inflammatory state can instead limit tissue repair. This persistent and excessive neuroinflammation can lead not only to further tissue damage but also to poor neurocognitive outcomes in the recovery phase after nerve injury. Therefore, understanding the mechanisms involved in microglia during brain tissue damage and recovery is important for later prediction and identification of therapeutic targets [6,11].

2. Mechanisms in Activation of Microglia Following ICH

2.1. Activated M1 Microglia

After ICH, M1 microglia are activated to play a major role in phagocytosis and removal of necrotic neurons and cellular debris to reduce the release of harmful substances of inflammatory cytokines and chemokines [12]. However, as the number of M1 cells increases, phagocytosis decreases significantly and the secretion of inflammatory cytokines, chemokines, and other neurotoxic mediators increases, leading to extensive cellular damage [10]. In addition, protein hydrolases (e.g., metalloproteases) lead to disruption of the
extracellular matrix and cellular integrity [13]. After brain injury, activated microglia are involved in oxidative stress and damage the blood–brain barrier; in addition, excess NO production from hemoglobin in the blood can also lead to the high permeability of the blood–brain barrier [14]. On this basis, the secretion of M1 microglia-specific chemokines leads to the infiltration and recruitment of blood-derived leukocytes, which exacerbates the inflammatory response and exacerbates neuronal death caused by excitotoxicity or oxygen-glucose deprivation [15]. Nuclear factor-κB (NF-κB) is a conventional transcription factor activated by lipopolysaccharide and regulates the expression of genes characteristic of most M1 phenotype microglia, namely pro-inflammatory cytokine genes [16]. In human brain tissue, NF-κBp65 was detected by immunohistochemistry to be expressed in the nucleus of glial cells [17], and was associated with elevated IL-1β and tumor necrosis factor (TNF). In clinical studies of perihematomal brain tissue, NF-κB was activated and migrated to the nucleus 13–48 h after ICH, and IL-1β and TNF were elevated within one day after ICH [18]. These findings suggest a pro-inflammatory state early after ICH. In rodents, collagenase [19] and autologous blood [19,20] induced ICH models, and secretion of pro-inflammatory cytokines IL-1β, IL-6, and TNF were increased in the first three days [21], and returned to the normal range on day 7. The study shows that TNF receptor antagonist R-7050 attenuates neurovascular injury and improves function in mice with collagenase-induced ICH [22]. In addition, interferon gamma (IFN-γ) polarizes microglia to the M1 state and significantly increases the number of microglia expressing iNOS, thereby increasing the number of M1-polarized cells [23,24]. Studies have shown high expression of M1 markers such as CD16, CD32, and iNOS on microglia on days 1 and 3 after ICH [25], indicating that M1-like polarization of microglia occurs early in the acute phase of ICH. Most pro-inflammatory cytokine levels return to baseline 14 days after ICH [26]. However, it is unclear whether these cytokine levels change during the chronic phase of ICH and whether they affect the brain repair process.

In a collagenase and an autologous blood-induced mouse model of ICH, Toll-like receptor (TLR)2 and TLR4 proteins on microglia exhibited upregulation 6 h after ICH and remained high for the first three days [20,25], and increased expression of TLR2 and TLR4 proteins were detrimental to the prognosis of patients with ICH [27]. TLR4 can promote the inflammatory response by activating the NF-κB signaling pathway through the myeloid differentiation primary response protein MYD88, and the TIR structural domain-containing junction molecule 2 [28,29], and TLR4 antagonists can reduce the production of pro-inflammatory cytokines (IL-1β, IL-6, TNF) after intervention [30]. In addition, TLR2-TLR4 heterodimers trigger inflammatory responses, suggesting a role for TLR2 in brain hemorrhage similar to that of TLR4 [31]. It was found that the levels of IL-1β, IL-6, and TNF were significantly lower in TLR2 and TLR4 knockout mice after brain hemorrhage than in wild-type mice [20,31], thus supporting the link between TLR2 and TLR4 activation and M1 microglia. In addition, high mobility group protein 1 (HMGB1) was found to promote M1 microglia polarization by increasing TLR2 and TLR4 signaling [32]. HMGB1 is a classical damage-associated molecular pattern usually localized in the nucleus as a DNA-binding protein and involved in nucleosome formation and the stabilization of gene transcription. HMGB1 is upregulated in neural and immune cells after brain injury. It activates the myelid differentiation primary response protein (MyD88)/NF-κB pathway downstream of TLR on the microglia surface, generating M1-type microglia polarization and releasing pro-inflammatory factors, leading to further neuronal damage [33]. Gao et al. treated TBI mice with the HMGB1 inhibitor glycyrrhizin (GL). They showed a decrease in the expression of M1 pro-inflammatory cytokines and their mRNA and an increase in the number of M2-type microglia [33].

2.2. Activated M2 Microglia

Microglia can promote cerebral edema and cellular debris clearance, promote cerebral angiogenesis, and improve neurological function through alternate activation of the M2 phenotype. Expression of M2 signature anti-inflammatory cytokines is also seen after ICH.
IL-10 is secreted by microglia and macrophages and can induce differentiation of microglia and macrophages cultured in vitro to the M2c subtype [34,35], and enhance phagocytosis of monocytes [36]. In addition, IL-10 also induces production of suppressor of cytokine signalling (SOCS)1 and SOCS3, where SOCS3 inhibits macrophage pro-inflammatory cytokine production via signal transducer and activator of transcription (STAT) 3 [37]. STAT3, a member of the STAT family, is involved in various abnormal CNS pro-inflammatory responses. The STAT3 signaling pathway is involved in pro-inflammatory responses associated with the M1 phenotype, which may contribute to early brain injury in subarachnoid hemorrhage (SAH). It was shown that microglia-specific STAT3 deficiency upregulates the expression of major anti-inflammatory factors such as IL-4 and enhances anti-inflammatory function by triggering microglia polarization from M1 to M2, thereby reducing neuroinflammatory response after SAH and improving neurological dysfunction and neuronal apoptosis [38]. Studies have found elevated levels of IL-10 in the blood [39] and brain tissue of patients with ICH [40], and upregulation of early IL-10 expression correlates with rebleeding following ICH [41]. IL-13 and IL-4 are anti-inflammatory cytokines that promote M2 microglia polarization. IL-13 is secreted by Th2 cells and shares a receptor subunit with IL-4, which is secreted by Treg cells and Th2 cells, both signaling through the Janus activated kinase (JAK)-STAT6 pathway [42], and upregulates the expression of M2 microglia, including Arg-1 and chitinase-like protein 3 (YM1) in microglia type microglia marker expression [43–45]. In addition, IL-4 is thought to drive microglia polarization to the M2 type [23]. Studies have shown that intracerebral injection of IL-4 inhibits M1 microglia polarization and promotes M2 microglia, thereby improving recovery from neurological dysfunction after ICH [46]. IL-4 and TGF-β1 have anti-inflammatory effects [26,46], and promote M2 microglia response and functional recovery after ICH. In addition to IL-4 and IL-10, low-density lipoprotein receptor-related protein-1 (LRP1) also enhanced the M2 polarization of microglia after acute brain injury and improved neurological injury [47]. In addition, concomitant administration of cyclic adenosine monophosphate (cAMP) and IL-4 resulted in upregulation of Arg-1 expression, a phenotypic marker of M2 in mice with TBI, and also reduced reactive oxygen species (ROS) production in mice [48]. In collagenase and blood-induced ICH models, M2-type marker levels change differently. For example, most M2 markers such as IL-1 receptor antagonist [49], IL-10 [50], Arg-1, YM1, and CD206 mRNA [46] showed elevated expression levels within one day after collagenase-induced ICH, whereas TGF-β1, IL-4 mRNA, and protein expression levels showed a significant increase until three days after ICH [21,49]. In the blood-induced ICH model, IL-13 expression levels were upregulated only in the first three days and TGF-β1 in the first ten days, while IL-10 was unchanged in the first two weeks, and in addition, IL-4 expression was not detected in the perihematoma brain tissue [26].

Peroxisome proliferator-activated receptor-γ (PPARγ) belongs to the nuclear receptor superfamily and plays an important role in antioxidant and anti-inflammatory responses [51]. The binding of PPARγ to DNA in nuclear extracts was inhibited one hour after blood-induced ICH in rats. At the same time, PPAR-γ agonists were found to reduce the activation of NF-κB [52] and decrease the levels of M1 microglia pro-inflammatory factors, such as iNOS, TNF, and IL-1 [53], in addition to promoting microglia in vitro by inducing the expression of CD36 protein phagocytosis of erythrocytes in vitro, which contributes to hematoma clearance [54]. Studies have shown that statins can reduce neuroinflammation by activating PPAR while interfering with NF-κB activity and downregulating the expression of pro-inflammatory cytokines such as IL-6 and IL-23, in addition to promoting the secretion of IL-4 and the polarization of the M2 phenotype [55].

Serine/threonine protein kinase (mTOR) signaling regulates immune responses in many neurological diseases, including traumatic brain injury and Alzheimer’s [56]. Inhibition of mTOR signaling reduces deleterious microglial activity and promotes anti-inflammatory M2 polarization [57]. ICH leads to dysregulation of mTOR activation, while rapamycin and AZD8055, mTOR inhibitors, improve early brain injury by inhibiting IL-1β and TNF production [58]. In addition, in collagenase-induced ICH rats, phosphorylation
of mTOR was significantly increased within 30 min, while rapamycin treatment resulted in a dose-dependent increase in the expression levels of the M2 microglia markers IL-10 and TGF-β and the ratio of IL-10 to IFNγ [59]. In addition, rapamycin intervention has been shown to reduce the expression levels of TNF, IL-1β, and IL-6 [60], and this evidence suggests a link between mTOR inhibition and M2 microglia (Figure 1), (Table 1).

![Figure 1. Mechanism of microglia polarization after cerebral hemorrhage.](image)

Activation of high-mobility histone 1 (HMG1) and Toll-like receptor (TLR)2 or TLR4 promotes M1-like responses in microglia via the NF-κB pathway. Binding of IFNγ to the receptor promotes microglia polarization to the M1 state. STAT6 accumulates in response to IL-4 and is responsible for transcription of M2-associated genes. IL-13 and IL-4 upregulate the expression of M2 microglia markers, including Arg-1 and YM1, in microglia via the JAK-STAT6 pathway. IL-10 inhibits the production of anti-inflammatory factors. Sphingosine-1-phosphate (S1P) receptor signalling contributes to the downregulation of proinflammatory cytokines and enhances M2-like responses after ICH; MYD88, myeloid differentiation primary response protein MYD88; TRIF, TIR domain-containing adaptor molecule 1; PPARγ, Peroxisome proliferator-activated receptor-γ.
Table 1. Markers and function of M1 and M2 microglia.

| Phenotype | Marker  | Type               | Function                                                | References       |
|-----------|---------|-------------------|---------------------------------------------------------|------------------|
| M1        | IL-1β   | Cytokine          | Proinflammatory                                         | [18,21,30]       |
| M1        | IL-6    | Cytokine          | Proinflammatory                                         | [21]             |
| M1        | TNF     | Cytokine          | Proinflammatory                                         | [21]             |
| M1        | IFN-γ   | Cytokine          | Proinflammatory, M1 microglia, and macrophage inducer   | [23,24]          |
| M1        | iNOS    | Metabolic enzyme  | Mediates nitric oxide synthesis                         | [23,24]          |
| M1        | CD16    | Immunoglobulin Fc receptor | Induces proinflammatory signalling              | [25]             |
| M1        | CD32    | Immunoglobulin Fc receptor | Induces proinflammatory signalling              | [25]             |
| M1        | CD86    | Surface receptor  | Classic M1 microglia and macrophage marker             | [61]             |
| M1        | CCL5    | Chemokine         | Recruits immune cells                                   | [62]             |
| M1        | CCL20   | Chemokine         | Recruits immune cells                                   | [63]             |
| M1        | CXCL1   | Chemokine         | Recruits immune cells                                   | [64]             |
| M1        | CXCL10  | Chemokine         | Recruits immune cells                                   | [65]             |
| M1        | MHC-II  | Surface receptor  | Mediates T cell differentiation to Th1                  | [66]             |
| M2        | IL-4    | Cytokine          | Anti-inflammatory, increases microglia and macrophage phagocytosis | [42]             |
| M2        | IL-10   | Cytokine          | Anti-inflammatory, mediates microglia and macrophage phagocytosis | [50]             |
| M2        | IL-13   | Cytokine          | Anti-inflammatory                                       | [42]             |
| M2        | TGF-β   | Cytokine          | Anti-inflammatory                                       | [26,46]          |
| M2        | Arg-1   | Cytosolic enzyme  | Suppresses inflammation; upregulated by IL-4 and IL-13 | [48]             |
| M2        | YM1     | Secretory protein | Anti-inflammatory; induction depends on IL-4 and IL-13  | [46]             |
| M2        | CCL22   | Chemokine         | Recruits dendritic cells, Th2 cells and regulatory T cells | [46]             |
| M2        | CD163   | Scavenger receptor | Haemoglobin clearance                                   | [67]             |
| M2        | CD206   | Mannose receptor  | Mediates endocytosis and phagocytosis in response to microglia and macrophage activation | [46]             |

Arg-1, arginase 1; CCL, chemokine (CC motif) ligand; CD206, macrophage mannose receptor 1; CXCL, chemokine (CXC motif) ligand; IFN-γ, interferon gamma; iNOS, inducible nitric oxide synthase; MHC-II, major histocompatibility complex-I; TGF-β, transforming growth factor-β; TNF, tumour necrosis factor; YM1, chitinase like protein 3.

3. Therapeutic Targets for Microglia Polarization

When developing targeted therapies to alter microglia polarization, it is important to consider the range of targets available, such as enzymes, cell surface markers, transcription factors, and signaling proteins. Because these affect the inflammatory signaling cascade induced in M1 or M2 microglia, strategies to mitigate inflammatory damage due to brain hemorrhage are very important. Over the years, many bioactive drugs derived from different natural resources have been identified as effective therapeutic approaches. In addition, previous studies have shown that upregulation of M2 microglia expression by natural products or compounds effectively reduces neuroinflammatory responses. Therefore, developing compounds that modulate M1/M2 polarization has been considered a beneficial therapeutic strategy for neurological diseases.
3.1. Enzymes as Targets

3.1.1. AMP-Activated Protein Kinase

AMP-activated protein kinase (AMPK) is a metabolism-sensitive serine/threonine protein kinase involved in transitioning from a pro-inflammatory M1 phenotype to an M2 phenotype. It plays a central role in regulating the pathogenesis of neuroinflammation and central nervous system diseases [69]. Recent studies have shown that activation of AMPK significantly promotes macrophage polarization toward the M2 phenotype to suppress the inflammatory response [70]. PPARγ regulates multiple pathways involving inflammation, carbohydrate, and lipid metabolism. In addition, PPARγ activation inhibits inflammatory responses and plays an important role in neuroprotection. The angiotensin II receptor blocker (ARB) telmisartan has potent neuroprotective effects in neurodegenerative diseases, promoting M2 polarization and decreasing M1 polarization in endotoxin-stimulated BV2 and primary microglia, the effects of which are partially dependent on PPARγ activation; in addition, AMPK inhibitors or AMPK knockdown attenuate the promoting effect of telmisartan on M2 polarization. It was shown that telmisartan enhanced brain AMPK activation and M2 gene expression in a mouse model of lipopolysaccharide-induced neuroinflammation. Although different functions activate AMPK and PPARγ pathways, they are both involved in lipopolysaccharide-induced M2 polarization in microglia. Both reduce the expression of inflammatory genes and protect energy metabolism [71]. Quercetin is a natural polyphenol with several biological properties, including antioxidant and anti-inflammatory effects [72], and also exerts neuroprotective effects in neurodegenerative diseases [73]. Quercetin not only decreased the expression of M1 markers such as IL-6, TNF-α, and IL-1β in microglia but also decreased M1 polarization-related chemokines. In addition, quercetin increases the levels of M2 marker IL-10 and endogenous antioxidant heme oxygenase (H2O)-1 through the activation of AMPK and protein kinase B(AKT) signaling pathways. It is expected to be a potential drug for treating inflammatory diseases of the central nervous system [74].

3.1.2. Matrix Metalloproteinase (MMP) 3/9

Matrix metalloproteinase (MMP) 3/9 may disrupt the blood–brain barrier and play an important role in ICH. Sinomenine is an active alkaloid extracted from the plant Sinomenine acutum, which produces an anti-inflammatory response and modulates the immune system [75]. Sinomenine inhibits microglia infiltration and activation in vivo and in vitro and mediates apoptosis of hippocampal neurons by inhibiting the caspase-3 activity of microglia. In addition, Sinomenine attenuated MMP-3/9 expression, brain water content, and neurological damage in ICH, suggesting that Sinomenine is an immunomodulator of microglia polarization, inhibits microglia M1 polarization, and promotes M2 polarization, contributing to inflammation regulation and cerebral protection, providing new clues for the potential treatment of ICH [76,77].

3.1.3. Janus-Activated Kinase

A Janus-activated kinase (JAK)-STAT pathway regulates cell proliferation, immunity, apoptosis, and inflammation [78]. Erythropoietin (EPO) is a pleiotropic cytokine reported to prevent neuronal apoptosis in many cerebrovascular diseases [79,80]. Janus family tyrosine-protein kinase JAK2 plays a central role in erythropoietin receptor (EPOR) downstream signaling. At the same time, phosphorylation of STAT3 is located downstream of p-JAK2. EPO amplifies the oxyhemoglobin (OxyHb)-induced increase in p-JAK2 and p-STAT3, while the JAK2 inhibitor AZD1480 blocked the EPO-stimulated-induced upregulation of p-STAT3. It was shown that EPO decreased the gene expression of pro-inflammatory cytokine genes (tumor necrosis factor-α and IL-1β) and increased the expression of anti-inflammatory cytokine genes (IL-4 and IL-10) in vivo and in vitro. However, EPOR knockdown and AZD1480 reversed the EPO-mediated changes in pro-inflammatory cytokine gene and anti-inflammatory cytokine gene expression after OxyHb stimulation, i.e., EPO may have promoted microglia M2 polarization through activation of the JAK2/STAT3 pathway [81,82].
3.2. Targeting Protein Receptors

3.2.1. Tropomyosin-Related Kinase

Tyrosine kinase receptors of the Trk family (TrkA, TrkB, TrkC) play a key role in the recovery after brain injury [83]. The TrkB/brain-derived growth factor (BDNF) pathway is widely recognized as a key pathway for repair after brain injury [84]. Minocycline exerts neuroprotective effects by promoting the secretion of neurotrophic factors from M2 microglia through the TrkB/BDNF pathway [85]. Minocycline is a semi-synthetic second-generation tetracycline derivative that readily penetrates the blood–brain barrier and is widely used to reduce bacterial load and inflammation [86]. It was shown that minocycline decreased the proliferation of CD68+ cells and increased the number of arginase 1 + CD16+ cells induced by ICH, suggesting that minocycline promotes the conversion of M1 microglia to M2 type after ICH in rats. In addition, minocycline significantly increased the expression of M2 microglia-derived BDNF around neuronal cells [85].

3.2.2. Peroxisome Proliferator-Activated Receptor-γ

Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear hormone receptor family and is thought to be involved in regulating a variety of metabolic, endocrine, and cardiovascular diseases [87]. Rosiglitazone, a PPARγ agonist, significantly improves the pathological changes in the brain’s white matter after stroke while protecting the white and gray matter of the brain and promoting long-term functional recovery after stroke. In vitro and in vivo studies have shown that rosiglitazone exerts protective effects on neurons, reduces oxidative stress, and attenuates excitotoxicity by promoting endogenous oligodendrocyte differentiation and microglia differentiation toward the M2 phenotype (including Arg1, IL-10) [88,89]. 10-O-(N, N dimethylaminoethyl)-ginkgolide B methanesulfonate (XQ-1H) is a new derivative of ginkgolide B with a strong platelet-activating factor antagonistic effect [90]. It was shown that co-expression of CD16 and Iba1 was significantly reduced, and co-expression of CD206 and Iba1 was increased in response to XQ-1H, indicating that XQ-1H affects microglia polarization by activating the PPARγ signaling pathway to promote the anti-inflammatory phenotype (CD16) and inhibit the pro-inflammatory phenotype (CD206) [91]. The herbal chemical constituent of forsythia, forsythoside, has various biological functions, such as improving islet resistance [92], regulating apoptosis and oxidative stress [93], and antiviral and anti-inflammatory activities of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) have antiviral and anti-inflammatory activities [94]. It was shown that coniferin could have anti-inflammatory effects by promoting microglia M2 polarization through the PPARγ/NF-κB pathway. It could also reduce microglia-induced blood–brain barrier damage after brain injury, improving its post-ischemic tissue damage [47].

3.2.3. Toll-Like Receptors

Toll-like receptor 4 (TLR4) is a key regulator of microglia activation and their polarization after brain injury [95]. Inhibition of TLR4 signaling attenuates neurological deficits by modulating the M1/M2 phenotypic shift in microglia in a mouse model of traumatic brain injury [96]. Caryophyllene (β-caryophyllene, BCP) is a natural bicyclic sesquiterpene with a variety of biological and pharmacological effects such as analgesic [97,98], anti-inflammatory [99,100], antioxidant [101], and prevention of apoptosis [102]. BCP is a small lipolytic molecule that can cross the blood–brain barrier [103]. It was found that, in wild-type mice and TLR4 knockout mice, BCP inhibited the polarization of microglia toward the M1 phenotype and promoted polarization toward the M2 phenotype. Furthermore, in vitro, BCP mediated the activation and polarization of primary microglia induced by the combination of lipopolysaccharide and interferon-γ. This effect of BCP was accompanied by downregulation of TLR4 and CD16/32 and upregulation of CD206 and was enhanced by blocking TLR4 activity. These findings suggest that TLR4 is an important target of BCP and that its protective effects are exerted, at least in part, through TLR4-mediated microglia activation and promotion of microglia polarization toward a beneficial M2 phe-
Pinocembrin (5,7-dihydroxyflavanone) is a natural product extracted from propolis with neuroprotective, anti-inflammatory, and oxidative stress-reducing effects. Pinocembrin reduces the number of classically activated M1-like microglia and decreases the activation of M1-associated cytokines and markers (IL-1β, IL-6, TNF-α, and iNOS), NF-κB, and the expression of TLR4 and its downstream target proteins TIR domain-containing adaptor molecule 1 (TRIF) and MyD88. Moreover, inhibition of the TLR4 signaling pathway and reduction of M1-like microglia polarization may be the main mechanism of pinocembrin protection against hemorrhagic brain injury. These findings suggest that the pinocembrin may potentially treat brain hemorrhage and other acute brain injuries.

3.3. Targeting Transcription Factors

3.3.1. PPARγ Coactivator-1α

PPARγ coactivator-1α (PGC-1α) is a transcriptional co-activator of nuclear receptors that plays a key integrative role in the transcriptional regulation of cellular energy metabolism, oxidative stress defense, mitochondrial function, and biogenesis. A recent study developed that PGC-1α inhibits endotoxin-induced M1 activation by suppressing NF-κB activity and promotes microglia polarization to the M2 phenotype by activating the STAT6 and STAT3 pathways. Resveratrol is a natural polyphenol with pharmacological effects such as anti-inflammatory, anti-apoptotic, and antioxidant effects, in addition to penetrating the blood–brain barrier, inhibiting the activation of glial cells, and reducing the production of pro-inflammatory factors. Studies have shown that resveratrol activates silent information regulator-1 (SIRT1), upregulates PGC-1α expression, attenuates inflammatory damage, and promotes microglia differentiation to the M2 phenotype.

3.3.2. Nuclear Factor-κB

Nuclear factor-κB (NF-κB) is a conventional transcription factor activated by lipopolysaccharide and regulates the expression of most M1 marker genes (genes for pro-inflammatory cytokines). Anisol (p-methoxybenzyl alcohol, PMBA) is isolated from the natural medicine Gastrodia. PMBA significantly reduced lipopolysaccharide-induced production of tumor necrosis factor-alpha, prostaglandin E2 (PEG-2), and nitric oxide without cytotoxicity. In addition, it increased the levels of anti-inflammatory factor IL-10 and TGF-β. Phenotypic analysis after lipopolysaccharide stimulation of microglia showed that PMBA significantly downregulated the expression of the M1 microglia marker CD16/32 and upregulated the expression of the M2 microglia marker CD206, with the possible mechanism of reducing the production of inflammatory mediators and cytokines by inhibiting the activation of NF-κB and mitogen-activated protein kinase (MAPK). Fingolimod (FTY720) is a sphingosine-1-phosphate (S1P) receptor one antagonist, and studies have shown that S1P1 significantly reduces the inhibitory effect of FTY720 on the production of tumor necrosis factor-α by activated microglia, suggesting that FTY720 inhibits the production of pro-inflammatory cytokines by microglia via S1P1. In contrast, the signaling pathway downstream of S1P1 inhibits NF-κB activation by downregulating histone deacetylase (HDAC), leading to the downregulation of pro-inflammatory cytokines and promoting the expression of neurotrophic factors with neuroprotective effects. In addition, FTY720 can control important inflammatory gene targets by regulating STAT1 levels at promoter sites, thereby inhibiting STAT1 autophagy and converting pro-inflammatory microglia into anti-inflammatory microglia. Tanshinone IIA is a lipid-soluble diterpenoid isolated from Salvia miltiorrhiza, which has been shown in several studies to have neuroprotective effects against cerebral ischemic injury through inhibition of inflammation and autophagy. Studies have shown that tanshinone IIA inhibits M1 microglia polarization and promotes M2 cell polarization through the NF-κB pathway, thereby suppressing the inflammatory response. Baicalein (5,6,7-trihydroxyflavonoids) is the main bioactive component extracted from the roots of Scutellaria baicalensis, a commonly used herbal medicine. Baicalein significantly decreased the expression of M1 markers CD16 and CD86 and increased the expression of...
M2 markers CD163 and CD206, suggesting that baicalein inhibits M1 polarization and promotes microglia/macrophage M2 polarization, thereby suppressing neuroinflammation. In addition, baicalein inhibits NF-κB signaling by reducing the phosphorylation and nuclear translocation of IkBα, thereby reducing the release of pro-inflammatory factors IL-6, IL-18, and TNF-α [117].

3.4. Targeting Inflammatory Vesicles

NLRP3 Infammasomes

NLRP3 infammasomes is a multi-protein complex that regulates the maturation and secretion of pro-inflammatory cytokines, including IL-1β and IL-18. Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active ingredient in peony root extract, was found to significantly inhibit NLRP3 inflammatory vesicle-associated protein levels in vivo and in vitro, reverse the effects of LPS/ATP on TLR4, MYD88, and p-p65/p65 protein levels and promote M2 polarization and inhibit M1 polarization in BV-2 cells, thereby suppressing the release of inflammatory cytokines [118]. Edaravone (EDA) shifts the M1 pro-inflammatory phenotype of microglia to an M2 anti-inflammatory state by decreasing the expression of M1 markers (TNFα and IL-1β) and promoting the expression of M2 markers (Arg-1 and IL-10). Furthermore, EDA suppressed the inflammatory response by inhibiting the expression of pro-inflammatory factors IL-1β, IL-18, and NO, but the neuroprotective effect of EDA was ineffective in the presence of siRNA-NLRP3, suggesting that EDA may exert anti-inflammatory effects by inhibiting NLRP3 inflammatory tissue activation and regulating microglia M1/M2 polarization [119] (Table 2).

| Type            | Target | Drug          | Effects on Microglia                                      | References |
|-----------------|--------|---------------|----------------------------------------------------------|------------|
| Enzymes         | AMPK   | Telmisartan   | Decreases M1-like microglial responses                    | [71]       |
|                 |        | Quercetin     | Decreases M1-like microglial responses                    | [74]       |
|                 | MMP3/9 | Sinomenine    | Decreases M1-like microglial responses                    | [76,77]    |
| Protein receptors | JAK   | Erythropoietin| Decreases M1-like microglial responses                    | [81,82]    |
|                 | Trk    | Minocycline   | Promotes M1-to-M2 phenotype shift                         | [85]       |
|                 | PPAR-γ | Rosiglitazone | Enhances M2-like microglial responses                     | [88,89]    |
|                 | TLR4   | Caryophyllene | Decreases M1-like microglial responses                    | [104]      |
|                 |        | Pinocembrin   | Decreases M1-like microglial responses                    | [25]       |
| Transcription factors | PGC-1α| Resveratrol   | Enhances M2-like microglial responses                     | [109]      |
|                 | NF-κB  | Anisol        | Decreases M1-like microglial responses                    | [112]      |
|                 |        | Fingolimod    | Decreases M1-like microglial responses                    | [114]      |
|                 |        | Tanshinone IIA| Decreases M1-like microglial responses                    | [116]      |
|                 |        | Baicalein     | Decreases M1-like microglial responses                    | [117]      |
Table 2. Cont.

| Type                     | Target | Drug     | Effects on Microglia                       | References |
|--------------------------|--------|----------|-------------------------------------------|------------|
| Inflammatory vesicles    | NLRP3  | Paeanol  | Decreases M1-like microglial responses     | [118]      |
|                          |        |          | Enhances M2-like microglial responses      |            |
|                          |        | Edaravone| Promotes M1-to-M2 phenotype shift          | [119]      |

AMPK, AMP-activated protein kinase; JAK, Janus-activated kinase; MMP3/9, Matrix metalloproteinase (MMP) 3/9; NF-κB, Nuclear factor-κB; NLRP3, NOD-like receptor thermal protein domain associated protein 3; PGC-1α, PPARγ coactivator-1α; PPAR-γ, Peroxisome proliferator-activated receptor-γ; TLR4, Toll-like receptor 4; Trk, Tropomyosin-related kinase.

### 4. Conclusions

Appropriate anti-brain hemorrhage therapy should promote the right microglia phenotype at the right time, thus maximizing the natural process of hematoma clearance and brain repair. Some drugs have now been validated in basic studies to have a reparative effect on secondary damage after ICH, where inhibition of M1-like microglia activation and enhancement of M2-like microglia anti-inflammatory response are the main mechanisms of action of these compounds. The next step in the search for therapies that selectively promote anti-inflammatory microglia phenotypic polarization is clinically important to improve the prognosis of ICH. In addition, existing studies suggest that interactions between microglia and astrocytes and oligodendrocytes may be beneficial or detrimental to neurons, but the crosstalk between the three has not been fully investigated. Further studies of astrocytes and oligodendrocyte mediators that regulate microglia polarization and phagocytosis will improve our understanding of the pathogenesis of ICH and lead to more effective therapeutic options for patients with ICH.

**Author Contributions:** Conceptualization, P.S., F.Z., T.Z. and H.L.; methodology, Y.G.; software, W.D.; validation, Y.Z., W.Q. and W.C.; formal analysis, L.P.; investigation, H.Z.; resources, P.S.; data curation, Y.G.; writing—original draft preparation, Y.G.; writing—review and editing, T.Z.; visualization, Y.G.; supervision, P.S.; project administration, H.L.; funding acquisition, P.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by the National Natural Science Foundation of China (NSFC, Nos. 81874419, 81673719, and 81303074), the National Health Commission of the People’s Republic of China (No. 2017ZX09301064002), the Natural Science Foundation of Shandong Province (Nos. ZR2020MB108, ZR2019MH063), and the Youth Innovation Team of Shandong University of Traditional Chinese Medicine (No. 2202112).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** All authors declare that there are no conflict of interest.

**References**

1. Magid-Bernstein, J.; Girard, R.; Polster, S.; Srinath, A.; Romanos, S.; Awad, I.A.; Sansing, L.H. Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions. *Circ. Res.* 2022, 130, 1204–1229. [CrossRef] [PubMed]
2. Zhu, H.; Wang, Z.; Yu, J.; Yang, X.; He, F.; Liu, Z.; Che, F.; Chen, X.; Ren, H.; Hong, M.; et al. Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage. *Prog. Neurobiol.* 2019, 178, 101610. [CrossRef] [PubMed]
3. Lan, X.; Han, X.; Li, Q.; Yang, Q.W.; Wang, J. Modulators of microglial activation and polarization after intracerebral haemorrhage. *Nat. Rev. Neurol.* 2017, 13, 420–433. [CrossRef] [PubMed]
4. Tschoe, C.; Bushnell, C.D.; Duncan, P.W.; Alexander-Miller, M.A.; Wolfe, S.Q. Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets. *J. Stroke* 2020, 22, 29–46. [CrossRef]
5. Fumagalli, S.; Perego, C.; Piscitutti, F.; Zanier, E.R.; De Simoni, M.G. The ischemic environment drives microglia and macrophage function. *Front. Neurol.* 2015, 6, 81. [CrossRef]
6. Hu, X.; Leak, R.K.; Shi, Y.; Suenaga, J.; Gao, Y.; Zheng, P.; Chen, J. Microglial and macrophage polarization—New prospects for brain repair. *Nat. Rev. Neurol.* 2015, 11, 56–64. [CrossRef]
7. Qin, C.; Zhou, L.Q.; Ma, X.T.; Hu, Z.W.; Yang, S.; Chen, M.; Bosco, D.B.; Wu, L.J.; Tian, D.S. Dual Functions of Microglia in Ischemic Stroke. *Neurosci. Bull.* 2019, 35, 921–933. [CrossRef]

8. Hu, X.; Li, P.; Guo, Y.; Wang, H.; Leak, R.K.; Chen, S.; Gao, Y.; Chen, J. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. *Stroke* 2012, 43, 3063–3070. [CrossRef]

9. Zhang, Z.; Zhang, Z.; Lu, H.; Yang, Q.; Wu, H.; Wang, J. Microglial Polarization and Inflammatory Mediators After Intracerebral Hemorrhage. *Mol. Neurobiol.* 54, 1874–1886. [CrossRef]

10. Zhao, H.; Garton, T.; Keep, R.F.; Hua, Y.; Xi, G. Microglia/Macrophage Polarization After Experimental Intracerebral Hemorrhage. *Transl. Stroke Res.* 2015, 6, 407–409. [CrossRef]

11. Yu, F.; Huang, J.; Ran, Y.; Li, D.; Ye, L.; Tian, G.; Xi, J.; Liu, Z. New Insights into the Roles of Microglial Regulation in Brain Plasticity-Dependent Stroke Recovery. *Front. Cell. Neurosci.* 2021, 15, 727899. [CrossRef]

12. Gomez-Nicola, D.; Perry, V. Microglial dynamics and role in the healthy and diseased brain: A paradigm of functional plasticity. *Neuroscientist* 2015, 21, 169–184. [CrossRef]

13. da Fonseca, A.C.; Mattias, D.; Garcia, C.; Amaral, R.; Geraldo, L.H.; Freitas, C.; Lima, F.R. The impact of microglial activation on blood-brain barrier in brain diseases. *Front. Cell. Neurosci.* 2014, 8, 362. [CrossRef]

14. Yang, S.; Chen, Y.; Deng, X.; Jiang, W.; Li, B.; Fu, Z.; Du, M.; Ding, R. Hemoglobin-induced nitric oxide synthase overexpression and nitric oxide production contribute to blood-brain barrier disruption in the rat. *J. Mol. Neurosci.* 2013, 51, 352–363. [CrossRef]

15. Yao, Y.; Tisrka, S.E. Chemokines and their receptors in intracerebral hemorrhage. *Transl. Stroke Res.* 2012, 3, 70–79. [CrossRef]

16. Taetzsch, T.; Levesque, S.; McGraw, C.; Brookins, S.; Luca, R.; Bonini, M.G.; Mason, R.P.; Oh, U.; Block, M.L. Redox regulation of NF-κB p50 and M1 polarization in microglia. *Glia* 2015, 63, 423–440. [CrossRef]

17. Zhang, Z.L.; Liu, Y.G.; Huang, Q.B.; Wang, H.W.; Song, Y.; Xu, Z.K.; Li, F. Nuclear factor-κB activation in perihematoma brain tissue correlates with outcome in patients with intracerebral hemorrhage. *J. Neuroinflammation* 2015, 12, 53. [CrossRef]

18. Zhang, Z.; Liu, Y.; Huang, Q.; Su, Y.; Zhang, Y.; Wang, G.; Li, F. NF-κB activation and cell death after intracerebral hemorrhage in patients. *Neuro. Sci.* 2014, 35, 1097–1102. [CrossRef]

19. Liew, H.K.; Pang, C.Y.; Hsu, C.W.; Wang, M.J.; Li, T.Y.; Peng, H.F.; Kuo, J.S.; Wang, J.Y. Systemic administration of urocortin after intracerebral hemorrhage reduces neurological deficits and neuroinflammation in rats. *J. Neuroinflammation* 2012, 9, 13. [CrossRef]

20. Lin, S.; Yin, Q.; Zhong, Q.; Lv, F.L.; Zhou, Y.; Li, J.Q.; Wang, J.Z.; Su, B.Y.; Yang, Q.W. Heme activates TLR4-mediated inflammatory injury via MyD88/TRIF signaling pathway in intracerebral hemorrhage. *J. Neuroinflammation* 2012, 9, 46. [CrossRef]

21. Zhang, Y.; Yi, B.; Ma, J.; Zhang, L.; Zhang, H.; Yang, Y.; Dai, Y. Quercetin promotes neuronal and behavioral recovery by suppressing inflammatory response and apoptosis in a rat model of intracerebral hemorrhage. *Neurochem. Res.* 2015, 40, 195–203. [CrossRef]

22. King, M.D.; Alleyne, C.H., Jr.; Dhandapani, K.M. TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice. *Neurosci. Lett.* 2013, 542, 92–96. [CrossRef]

23. Chauhan, P.; Hu, S.; Sheng, W.S.; Prasad, S.; Lokensgard, J.R. Modulation of Microglial Cell Fc Receptor Expression Following Viral Brain Infection. *Sci. Rep.* 2017, 7, 41889. [CrossRef]

24. Chauhan, P.; Sheng, W.S.; Hu, S.; Prasad, S.; Lokensgard, J.R. Differential Cytokine-Induced Responses of Polarized Microglia. *Brain Sci.* 2021, 11, 1482. [CrossRef]

25. Lan, X.; Han, X.; Li, Q.; Li, Q.; Gao, Y.; Cheng, T.; Wan, J.; Zhu, W.; Wang, J. Pinocembrin protects hemorrhagic brain primarily by inhibiting toll-like receptor 4 and reducing M1 phenotype microglia. *Brain Behav. Immun.* 2017, 61, 326–339. [CrossRef]

26. Taylor, R.A.; Chang, C.F.; Goods, B.A.; Hammond, M.D.; Mac Grory, B.; Ai, Y.; Steinschneider, A.F.; Renfroe, S.C.; Askenase, M.H.; McCullough, L.D.; et al. TGF-β1 modulates microglial phenotype and promotes recovery after intracerebral hemorrhage. *J. Clin. Investig.* 2017, 127, 280–292. [CrossRef]

27. Rodriguez-Yáñez, M.; Brea, D.; Arias, S.; Blanco, M.; Pumar, J.M.; Castillo, J.; Sobrino, T. Increased expression of Toll-like receptors 2 and 4 is associated with poor outcome in intracerebral hemorrhage. *J. Neuromun.rol. 2012*, 247, 75–80. [CrossRef]

28. Wang, Y.; Su, L.; Morin, M.D.; Jones, B.T.; Whitby, L.R.; Surakattula, M.M.; Huang, H.; Shi, H.; Choi, J.H.; Wang, K.W.; et al. TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. *Proc. Natl. Acad. Sci. USA* 2016, 113, E884–E893. [CrossRef]

29. Xiong, X.Y.; Liu, L.; Wang, F.X.; Yang, Y.R.; Hao, J.W.; Wang, P.F.; Zhong, Q.; Zhou, K.; Xiong, A.; Zhu, W.Y.; et al. Toll-Like Receptor 4/MyD88-Mediated Signaling of Hepcidin Expression Causing Brain Iron Accumulation, Oxidative Injury, and Cognitive Impairment After Intracerebral Hemorrhage. *Circulation* 2016, 134, 1025–1038. [CrossRef]

30. Wang, Y.C.; Wang, P.F.; Fang, H.; Chen, J.; Xiong, X.Y.; Yang, Q.W. Toll-like receptor 4 antagonist attenuates intracerebral hemorrhage-induced brain injury. *Stroke* 2013, 44, 2545–2552. [CrossRef]

31. Wang, Y.C.; Zhou, Y.; Fang, H.; Lin, S.; Wang, P.F.; Xiong, R.P.; Chen, J.; Xiong, X.Y.; Lv, F.L.; Liang, Q.L.; et al. Toll-like receptor 2/4 heterodimer mediates inflammatory injury in intracerebral hemorrhage. *Ann. Neurol.* 2014, 75, 876–889. [CrossRef] [PubMed]

32. Karuppagounder, V.; Girdharan, V.V.; Arumugam, S.; Sreedhar, R.; Palaniyandi, S.S.; Krishnamurthy, P.; Quevedo, J.; Watanabe, K.; Konishi, T.; Thandavarayan, R.A. Modulation of Macrophage Polarization and HMGB1-TLR2/TLR4 Cascade Plays a Crucial Role for Cardiac Remodeling in Senescence-Accelerated Prone Mice. *PloS ONE* 2016, 11, e0152922. [CrossRef] [PubMed]

33. Gao, T.; Chen, Z.; Chen, H.; Yuan, H.; Wang, Y.; Peng, X.; Wei, C.; Yang, J.; Xu, C. Inhibition of HMGB1 mediates neuroprotection of traumatic brain injury by modulating the microglia/macrophage polarization. *Biochem. Biophys. Res. Commun.* 2018, 497, 430–436. [CrossRef] [PubMed]
34. Ardíc, S.; Cao, J.Z.; McSharry, B.P.; Clancy, L.E.; Brown, R.; Steain, M.; Gottlieb, D.J.; Abendroth, A.; Slobedman, B. Human cytomegalovirus interleukin-10 polarizes monocytes toward a deactivated M2c phenotype to repress host immune responses. *J. Virol.* 2013, 87, 10273–10282. [CrossRef]

35. Koscsó, B.; Csóka, B.; Kökai, E.; Németh, Z.H.; Pacher, P.; Virág, L.; Leibovich, S.J.; Haskó, G. Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages. *J. Leukoc. Biol.* 2013, 94, 1309–1315. [CrossRef]

36. David, S.; Kroner, A. Repertoire of microglial and macrophage responses after spinal cord injury. *Nat. Rev. Neurosci.* 2011, 12, 388–399. [CrossRef]

37. Yoshimura, A.; Naka, T.; Kubo, M. SOCS proteins, cytokine signalling and immune regulation. *Nat. Rev. Immunol.* 2007, 7, 454–465. [CrossRef]

38. Zheng, Z.V.; Chen, J.; Lyu, H.; Lam, S.Y.E.; Lu, G.; Chan, W.Y.; Wong, G.K.C. Novel role of STAT3 in microglia-dependent neuroinflammation after experimental subarachnoid haemorrhage. *Stroke Vasc. Neurology* 2022, 7, 62–70. [CrossRef]

39. Shi, L.; Qin, J.; Song, B.; Wang, Q.M.; Zhang, R.; Liu, X.; Liu, Y.; Hou, H.; Chen, X.; Ma, X.; et al. Increased frequency of circulating regulatory T cells in patients with acute cerebral hemorrhage. *Neurosci. Lett.* 2015, 591, 115–120. [CrossRef]

40. Liu, B.; Hu, B.; Sos, S.; Wu, W.; Fan, L.; Bai, G.; Shang, P.; Wang, X. CD163/Hemoglobin Oxygenase-1 Pathway Regulates Inflammation in Hematoma Surrounding Tissues after Intracerebral Hemorrhage. *J. Stroke Cerebrovasc. Dis.* 2015, 24, 2800–2809. [CrossRef]

41. Wang, K.W.; Cho, C.L.; Chen, H.J.; Liang, C.L.; Liliang, P.C.; Tsai, Y.D.; Wang, H.K.; Lu, K. Molecular biomarker of inflammatory response is associated with rebleeding in spontaneous intracerebral hemorrhage. *Eur. Neurol.* 2011, 66, 322–327. [CrossRef]

42. Junttila, I.S. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes. *Front. Immunol.* 2018, 9, 888. [CrossRef]

43. Kolosowska, N.; Keuters, M.H.; Wojciechowski, S.; Keksa-Goldsteine, V.; Laine, M.; Malm, T.; Goldsteins, G.; Koistinaho, J.; Kolosowska, N.; Keuters, M.H.; Wojciechowski, S.; Keksa-Goldsteine, V.; Laine, M.; Malm, T.; Goldsteins, G.; Koistinaho, J.;... [CrossRef]

44. Quarta, A.; Le Blon, D.; A’Ees, T.; Pieters, Z.; Hamzai Taj, S.; Miró-Mur, F.; Luyckx, E.; Van Breedam, E.; Daans, J.; Goossens, H.; et al. Murine iPS-derived microglia and macrophage cell culture models recapitulate distinct phenotypical and functional properties of classical and alternative neuro-immune polarisation. *Brain Behav. Immun.* 2019, 82, 406–421. [CrossRef]

45. Aratake, T.; Higashi, Y.; Ueba, Y.; Hamada, T.; Shimizu, T.; Shimizu, S.; Yawata, T.; Ueba, T.; Saito, M. The inhibitory role of intracellular free zinc in the regulation of Arg-1 expression in interleukin-4-induced activation of M2 microglia. *Metallonics* 2018, 10, 1501–1509. [CrossRef]

46. Yang, J.; Ding, S.; Huang, W.; Hu, J.; Huang, S.; Zhang, Y.; Zhuge, Q. Interleukin-4 Ameliorates Functional Recovery of Intracerebral Hemorrhage Through the Alternative Activation of Microglia/Macrophage. *Front. Neurosci.* 2016, 10, 61. [CrossRef]

47. Jiang, Q.; Wei, D.; He, X.; Gan, C.; Long, X.; Zhang, H. Phyllin Prevents Neuroinflammation-Induced Blood-Brain Barrier Damage Following Traumatic Brain Injury via Altering Microglial Polarization. *Front. Pharmacol.* 2021, 12, 719823. [CrossRef]

48. Ghosh, M.; Xu, Y.; Pearse, D.D. Cyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines. *J. Neuroinflammation* 2016, 13, 9. [CrossRef]

49. Wasserman, J.K.; Zhu, X.; Schlichter, L.C. Evolution of the inflammatory response in the brain following intracerebral hemorrhage and effects of delayed minocycline treatment. *Brain Res.* 2007, 1180, 140–154. [CrossRef]

50. Liesz, A.; Middelhoff, M.; Zhou, W.; Karcher, S.; Illanes, S.; Veltkamp, R. Comparison of humoral neuroinflammation and adhesion molecule expression in two models of experimental intracerebral hemorrhage. *Exp. Transl. Stroke Med.* 2021, 8, 1304–1319. [CrossRef]

51. David, S.; Kroner, A. Repertoire of microglial and macrophage responses after spinal cord injury. *Nat. Rev. Neurosci.* 2011, 12, 388–399. [CrossRef]

52. Li, D.; Wang, C.; Yao, Y.; Chen, L.; Liu, G.; Zhang, R.; Liu, Q.; Shi, F.D.; Hao, J. mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type. *FASEB J.* 2016, 30, 3388–3399. [CrossRef]
58. You, W.; Wang, Z.; Li, H.; Shen, H.; Xu, X.; Jia, G.; Chen, G. Inhibition of mammalian target of rapamycin attenuates early brain injury through modulating microglial polarization after experimental subarachnoid hemorrhage in rats. J. Neurosci. 2016, 367, 224–231. [CrossRef] [PubMed]

59. Lu, Q.; Gao, L.; Huang, L.; Ruan, L.; Yang, J.; Huang, W.; Li, Z.; Zhang, Y.; Jin, K.; Zhuge, Q. Inhibition of mammalian target of rapamycin improves neurobehavioral deficit and modulates immune response after intracerebral hemorrhage in rat. J. Neuroinflammation 2014, 11, 44. [CrossRef] [PubMed]

60. Wang, J.P.; Zhang, M.Y. Role for Target of Rapamycin (mTOR) Signal Pathway in Regulating Neuronal Injury after Intracerebral Hemorrhage. Cell. Physiol. Biochem. 2017, 41, 145–153. [CrossRef] [PubMed]

61. Wachholz, S.; Eßlinger, M.; Plümper, J.; Manitz, M.P.; Juckel, G.; Friebe, A. Microglia activation is associated with IFN-α induced depressieve-like behavior. Brain Behav. Immun. 2016, 55, 105–113. [CrossRef]

62. Vogel, D.Y.; Heijnen, P.D.; Breur, M.; de Vries, H.E.; Tool, A.T.; Amor, S.; Dijkstra, C.D. Macrophages migrate in an activation-dependent manner to chemokines involved in neuroinflammation. J. Neuroinflammation 2014, 11, 23. [CrossRef]

63. Guedj, K.; Khallou-Laschet, J.; Clement, M.; Morvan, M.; Gaston, A.T.; Fornasa, G.; Dai, J.; Gervais-Taurel, M.; Eberl, G.; Michel, J.B.; et al. M1 macrophages act as LTβR-independent lymphoid tissue inducer cells during atherosclerosis-related lymphoid neogenesis. Cardiovasc. Res. 2014, 101, 434–443. [CrossRef]

64. Zhong, T.Y.; Arancibia, S.; Born, R.; Tampe, R.; Villar, J.; Del Campo, M.; Manubens, A.; Becker, M.I. Hemocyanins Stimulate Innate Immunity by Inducing Different Temporal Patterns of Proinflammatory Cytokine Expression in Macrophages. J. Immunol. 2016, 196, 4650–4662. [CrossRef]

65. Hennessy, E.; Griffith, E.W.; Cunningham, C. Astrocytes Are Primed by Chronic Neurodegeneration to Produce Exaggerated Chemokine and Cell Infiltration Responses to Acute Stimulation with the Cytokines IL-1β and TNF-α. J. Neurosci. 2015, 35, 8411–8422. [CrossRef]

66. Okuneva, O.; Körber, I.; Li, Z.; Tian, L.; Joensuu, T.; Kopra, O.; Lehesjoki, A.E. Abnormal microglial activation in the Cstb(-/-) mouse, a model for progressive myoclonus epilepsy, EPM1. Glia 2015, 63, 400–411. [CrossRef]

67. Peferoen, L.A.; Vogel, D.Y.; Ummenthum, K.; Breur, M.; Heijnen, P.D.; Gerritsen, W.H.; Peferoen-Baert, R.M.; van der Valk, P.; Dijkstra, C.D.; Amor, S. Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2015, 74, 48–63. [CrossRef]

68. Evans, B.J.; Haskard, D.O.; Sempowski, G.; Landis, R.C. Evolution of the Macrophage CD163 Phenotype and Cytokine Profiles in a Human Model of Resolving Inflammation. Int. J. Inflam. 2013, 2013, 780502. [CrossRef]

69. Amato, S.; Man, H.Y. Bioenergy sensing in the brain: The role of AMP-activated protein kinase in neuronal metabolism, development and neurological disorders. Cell Cycle 2011, 10, 3452–3460. [CrossRef]

70. Mournier, R.; Thérèse, M.; Arnold, L.; Cuvellier, S.; Bultot, L.; Göransson, O.; Sanz, N.; Ferry, A.; Sakamoto, K.; Foretz, M.; et al. AMPKα1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab. 2013, 18, 251–264. [CrossRef]

71. Xu, Y.; Xu, Y.; Wang, Y.; Wang, Y.; He, L.; Jiang, Z.; Huang, Z.; Liao, H.; Li, J.; Saavedra, J.M.; et al. Telmisartan prevention of injury in intracerebral hemorrhage. J. Neuroinflammation 2017, 14, 39. [CrossRef] [PubMed]

72. Li, Y.; Yao, J.; Han, C.; Yang, J.; Chaudhry, M.T.; Wang, S.; Liu, H.; Yin, Y. Quercetin, Inflammation and Kidney Injury in a Mouse Model of Obstructive Nephropathy. Nutrients 2016, 8, 167. [CrossRef] [PubMed]

73. Gan, L.; Johnson, J.A. Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases. Biochim. Biophys. Acta 2014, 1842, 1208–1218. [CrossRef] [PubMed]

74. Tsai, C.F.; Chen, G.W.; Chen, Y.C.; Shen, C.K.; Lu, D.Y.; Yang, L.Y.; Chen, J.H.; Yeh, W.L. Regulatory Effects of Quercetin on M1/M2 Macrophage Polarization and Oxidative/Antioxidative Balance. Nutrients 2021, 14, 67. [CrossRef]

75. Qin, T.; Du, R.; Huang, F.; Yin, S.; Yang, J.; Qin, S.; Cao, W. Sinominine activation of M2 microglia polarization via CaMKKβ-dependent AMPK activation. Brain Behav. Immun. 2015, 50, 298–313. [CrossRef] [PubMed]

76. Shi, H.; Zheng, K.; Su, Z.; Su, H.; Zhong, M.; He, X.; Zhou, C.; Chen, H.; Xiong, Q.; Zhang, Y. Sinominine enhances microglia M2 polarization and attenuates inflammatory injury in intracerebral hemorrhage. J. Neuroimmunol. 2016, 299, 28–34. [CrossRef]

77. Yang, Z.; Liu, Y.; Yuan, F.; Li, Z.; Huang, S.; Shen, H.; Yuan, B. Sinominine inhibits microglia activation and attenuates brain injury in intracerebral hemorrhage. Mol. Immunol. 2014, 60, 109–114. [CrossRef]

78. Jeon, S.B.; Yoon, H.J.; Chang, C.Y.; Koh, H.S.; Jeon, S.H.; Park, E.J. Galactin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J. Immunol. 2010, 185, 7037–7046. [CrossRef]

79. Ma, S.; Chen, J.; Chen, C.; Wei, N.; Xu, J.; Yang, G.; Wang, N.; Meng, Y.; Ren, J.; Xu, Z. Erythropoietin Rescues Memory Impairment in a Rat Model of Chronic Cerebral Hypoperfusion via the EPO-R/JAK2/STAT5/Pi3K/Akt/GSK-3β Pathway. Mol. Neurobiol. 2018, 55, 3290–3299. [CrossRef]

80. Wang, R.; Zhao, H.; Li, J.; Duan, Y.; Fan, Z.; Tao, Z.; Ju, F.; Yan, F.; Luo, Y. Erythropoietin attenuates axonal injury after middle cerebral artery occlusion in mice. Neurol. Res. 2017, 39, 545–551. [CrossRef]

81. Wei, S.; Luo, C.; Yu, S.; Gao, J.; Liu, C.; Wei, Z.; Zhang, Z.; Wei, L.; Yi, B. Erythropoietin ameliorates early brain injury after subarachnoid haemorrhage by modulating microglia polarization via the EPOR/JAK2-STAT3 pathway. Exp. Cell Res. 2017, 361, 342–352. [CrossRef]
82. Wang, R.; Zhang, S.; Yang, Z.; Zheng, Y.; Yan, F.; Tao, Z.; Fan, J.; Zhao, H.; Han, Z.; Luo, Y. Mutant erythropoietin enhances white matter repair via the JAK2/STAT3 and C/EBPβ pathway in middle-aged mice following cerebral ischemia and reperfusion. Exp. Neurol. 2021, 337, 113533. [CrossRef]

83. Patapoutian, A.; Reichardt, L.F. Trk receptors: Mediators of neurotrophin action. Curr. Opin. Neurobiol. 2001, 11, 272–280. [CrossRef]

84. Ploughman, M.; Windle, V.; MacLellan, C.L.; White, N.; Dore, J.J.; Corbett, D. Brain-derived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats. Stroke 2009, 40, 1490–1495. [CrossRef]

85. Miao, H.; Li, R.; Han, C.; Lu, X.; Zhang, H. Minocycline promotes posthemorrhagic neurogenesis via M2 microglia polarization via upregulation of the TrkB/BDNF pathway in rats. J. Neurophysiol. 2018, 120, 1307–1317. [CrossRef]

86. Daly, L.T.; Tsai, D.M.; Singh, M.; Nuutila, K.; Minasian, R.A.; Lee, C.C.Y.; Kiwanuka, E.; Hackl, F.; Onderdonk, A.B.; Junker, J.P.E.; et al. Topical Minocycline Effectively Decontaminates and Reduces Inflammation in Infected Porcine Wounds. Plast. Reconstr. Surg. 2016, 138, 856e–868e. [CrossRef]

87. Olefsky, J.M.; Glass, C.K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72, 219–246. [CrossRef]

88. Hasegawa-Moriyama, M.; Ohnou, T.; Godai, K.; Kurimoto, T.; Nakama, M.; Kanamura, Y. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuates postincisional pain by regulating macrophage polarization. Biochem. Biophys. Res. Commun. 2012, 426, 76–82. [CrossRef]

89. Han, L.; Cai, W.; Mao, L.; Liu, J.; Li, P.; Leak, R.K.; Xu, Y.; Hu, X.; Chen, J. Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia. Stroke 2015, 46, 2628–2636. [CrossRef]

90. Liu, W.; Li, P.; Feng, F.; Mao, L. Isolation and structure characterization of related impurities in 10-O-(N,N-dimethylaminoethyl)-ginkgolide B methanesulphonate (XQ-1H) bulk drug and quantitation by a validated RP-LC. J. Pharm. Biomed. Anal. 2010, 52, 603–608. [CrossRef]

91. Liu, R.; Diao, J.; He, S.; Li, B.; Fei, Y.; Li, Y.; Fang, W. XQ-1H protects against ischemic stroke by regulating microglia polarization and the JAK2/STAT3 and C/EBPβ signaling pathway in mice. Int. Immunopharmacol. 2018, 57, 72–81. [CrossRef]

92. Xu, X.; Saadeldeen, P.S.A.; Xu, L.; Zhao, Y.; Wei, J.; Wang, H.D.; Liu, Z.; Kang, W. The Mechanism of Phylliryn from the Leaves of Forsythia suspensa for Improving Insulin Resistance. Biomed. Res. Int. 2019, 2019, 3176483. [CrossRef]

93. Du, Y.; You, L.; Ni, B.; Sai, N.; Wang, W.; Sun, M.; Xu, R.; Yao, Y.; Zhang, Z.; Qu, C.; et al. Phylliryn Mitigates Apoptosis and Oxidative Stress in Hydrogen Peroxide-Treated RPE Cells through Activation of the Nrf2 Signaling Pathway. Oxid. Med. Cell. Longev. 2020, 2020, 2684672. [CrossRef]

94. Ma, Q.; Li, R.; Pan, W.; Huang, W.; Liu, B.; Xie, Y.; Wang, Z.; Li, C.; Jiang, H.; Huang, J.; et al. Phylliryn (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway. Phytotherapy 2020, 78, 153296. [CrossRef]

95. Aritiila, J.E.; Whitaker, K.W.; Wires, E.S.; Harvey, B.K.; Airavaara, M. Role of microglia in ischemic focal stroke and recovery: Focus on Toll-like receptors. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2017, 79, 3–14. [CrossRef]

96. Yao, X.; Liu, S.; Ding, W.; Yue, P.; Jiang, Q.; Zhao, M.; Hu, F.; Zhang, H. TLR4 signal ablation attenuated neurological deficits by regulating microglial M1/M2 phenotype after traumatic brain injury in mice. J. Neuroimmunol. 2017, 310, 38–45. [CrossRef]

97. Paula-Freire, L.I.; Andersen, M.L.; Gama, V.S.; Molska, G.R.; Carlini, E.L. The oral administration of trans-caryophyllene attenuates acute and chronic pain in mice. J. Neuroimmunol. 2014, 21, 356–362. [CrossRef]

98. Fidyt, K.; Fiedorowicz, A.; Strządala, L.; Szumny, A. β-caryophyllene and β-caryophyllene oxide-natural compounds of anticancer and analgesic properties. Cancer Med. 2016, 5, 3007–3017. [CrossRef]

99. Tian, X.; Peng, J.; Zhong, J.; Yang, M.; Pang, J.; Lou, J.; Li, M.; An, R.; Zhang, Q.; Xu, L.; et al. β-Caryophyllene protects in vitro neurovascular unit against oxygen-glucose deprivation and re-oxygenation-induced injury. J. Neurochem. 2016, 139, 757–768. [CrossRef]

100. Cheng, Y.; Dong, Z.; Liu, S. β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARγ pathway. Pharmacology 2019, 94, 1–12. [CrossRef]

101. Calleja, M.A.; Vieites, J.M.; Montero-Meléndez, T.; Torres, M.I.; Faus, M.J.; Gil, A.; Suárez, A. The antioxidant effect of β-caryophyllene protects rat liver from carbon tetrachloride-induced fibrosis by inhibiting hepatic stellate cell activation. Br. J. Nutr. 2013, 109, 394–401. [CrossRef][PubMed]

102. Zhang, Q.; An, R.; Tian, X.; Yang, M.; Li, M.; Lou, J.; Xu, L.; Dong, Z. β-Caryophyllene Pretreatment Alleviates Focal Cerebral Ischemia-Reperfusion Injury by Activating PI3K/Akt Signaling Pathway. Neurochem. Res. 2017, 42, 1459–1469. [CrossRef][PubMed]

103. Murata, K.; Matsumura, S.; Yoshioka, Y.; Ueno, Y.; Matsuda, H. Screening of β-secretase and acetylcholinesterase inhibitors from plant resources. J. Nat. Med. 2015, 69, 123–129. [CrossRef][PubMed]

104. Tian, X.; Liu, H.; Xiang, F.; Xu, L.; Dong, Z. β-Caryophyllene protects against ischemic stroke by promoting polarization of microglia toward M2 phenotype via the TLR4 pathway. Life Sci. 2019, 237, 116915. [CrossRef][PubMed]

105. Wu, C.X.; Liu, R.; Gao, M.; Zhao, G.; Wu, S.; Wu, C.F.; Du, G.H. Pinocembrin protects brain against ischemia/reperfusion injury by attenuating endoplasmic reticulum stress induced apoptosis. Neurosci. Lett. 2013, 546, 57–62. [CrossRef][PubMed]

106. Shi, L.L.; Chen, B.N.; Gao, M.; Zhang, H.A.; Li, Y.J.; Wang, L.; Du, G.H. The characteristics of therapeutic effect of pinocembrin in transient global brain ischemia/reperfusion rats. Life Sci. 2011, 88, 521–528. [CrossRef]
107. Katsouri, L.; Blondrath, K.; Sastre, M. Peroxisome proliferator-activated receptor-γ cofactors in neurodegeneration. *IUBMB Life* 2012, 64, 958–964. [CrossRef]

108. Tsunemi, T.; La Spada, A.R. PGC-1α at the intersection of bioenergetics regulation and neuron function: From Huntington’s disease to Parkinson’s disease and beyond. *Prog. Neurobiol.* 2012, 97, 142–151. [CrossRef]

109. Yang, X.; Xu, S.; Qian, Y.; Xiao, Q. Resveratrol regulates microglia M1/M2 polarization via PGC-1α in conditions of neuroinflammatory injury. *Brain Behav. Immun.* 2017, 64, 162–172. [CrossRef]

110. Fu, W.; Zhuang, W.; Zhou, S.; Wang, X. Plant-derived neuroprotective agents in Parkinson’s disease. *Am. J. Transl. Res.* 2015, 7, 1189–1202.

111. Duan, X.H.; Li, Z.L.; Yang, D.S.; Zhang, F.L.; Lin, Q.; Dai, R. Study on the chemical constituents of Gastrodia elata. *J. Chin. Med. Mater.* 2013, 36, 1608–1611.

112. Xiang, B.; Xiao, C.; Shen, T.; Li, X. Anti-inflammatory effects of anisalcohol on lipopolysaccharide-stimulated BV2 microglia via selective modulation of microglia polarization and down-regulation of NF-κB p65 and JNK activation. *Mol. Immunol.* 2018, 95, 39–46. [CrossRef]

113. Noda, H.; Takeuchi, H.; Mizuno, T.; Suzumura, A. Fingolimod phosphate promotes the neuroprotective effects of microglia. *J. Neuroimmunol.* 2013, 256, 13–18. [CrossRef]

114. Hu, Z.W.; Zhou, L.Q.; Yang, S.; Chen, M.; Yu, H.H.; Tao, R.; Wu, L.J.; Wang, W.; Zhang, Q.; Qin, C.; et al. FTY720 Modulates Microglia Toward Anti-inflammatory Phenotype by Suppressing Autophagy via STAT1 Pathway. *Cell. Mol. Neurobiol.* 2021, 41, 353–364. [CrossRef]

115. Huang, Y.; Long, X.; Tang, J.; Li, X.; Zhang, X.; Luo, C.; Zhou, Y.; Zhang, P. The Attenuation of Traumatic Brain Injury via Inhibition of Oxidative Stress and Apoptosis by Tanshinone IIA. *Oxid. Med. Cell. Longev.* 2020, 2020, 4170156. [CrossRef]

116. Song, Z.; Feng, J.; Zhang, Q.; Deng, S.; Yu, D.; Zhang, Y.; Li, T. Tanshinone IIA Protects Against Cerebral Ischemia Reperfusion Injury by Regulating Microglial Activation and Polarization via NF-κB Pathway. *Front. Pharmacol.* 2021, 12, 641848. [CrossRef]

117. Yang, S.; Wang, H.; Yang, Y.; Wang, R.; Wang, Y.; Wu, C.; Du, G. Baicalein administered in the subacute phase ameliorates ischemia-reperfusion-induced brain injury by reducing neuroinflammation and neuronal damage. *Biomed. Pharmacother.* 2019, 117, 109102. [CrossRef]

118. Zhao, H.; Wang, X.; Liu, S.; Zhang, Q. Paeonol regulates NLRP3 inflammasomes and pyroptosis to alleviate spinal cord injury of rat. *BMC Neurosci.* 2022, 23, 16. [CrossRef]

119. Li, J.; Dai, X.; Zhou, L.; Li, X.; Pan, D. Edaravone Plays Protective Effects on LPS-Induced Microglia by Switching M1/M2 Phenotypes and Regulating NLRP3 Inflammasome Activation. *Front. Pharmacol.* 2021, 12, 691773. [CrossRef]